AR114270A1 - Compuestos de 4-metildihidropirimidinona y su uso farmacéutico - Google Patents
Compuestos de 4-metildihidropirimidinona y su uso farmacéuticoInfo
- Publication number
- AR114270A1 AR114270A1 ARP190100480A ARP190100480A AR114270A1 AR 114270 A1 AR114270 A1 AR 114270A1 AR P190100480 A ARP190100480 A AR P190100480A AR P190100480 A ARP190100480 A AR P190100480A AR 114270 A1 AR114270 A1 AR 114270A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyldihydropyrimidinone
- compounds
- pharmaceutical use
- pharmaceutical
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) ó (2), o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018035597 | 2018-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114270A1 true AR114270A1 (es) | 2020-08-12 |
Family
ID=67805061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190100480A AR114270A1 (es) | 2018-02-28 | 2019-02-27 | Compuestos de 4-metildihidropirimidinona y su uso farmacéutico |
Country Status (19)
Country | Link |
---|---|
US (2) | US10899717B2 (es) |
EP (1) | EP3760616A4 (es) |
JP (1) | JP7282546B2 (es) |
KR (1) | KR20200126973A (es) |
CN (1) | CN111741947B (es) |
AR (1) | AR114270A1 (es) |
AU (1) | AU2019228915A1 (es) |
BR (1) | BR112020016785A2 (es) |
CA (1) | CA3087994A1 (es) |
CL (1) | CL2020002187A1 (es) |
CO (1) | CO2020011860A2 (es) |
IL (1) | IL276323A (es) |
MX (1) | MX2020008982A (es) |
PE (1) | PE20210550A1 (es) |
PH (1) | PH12020551341A1 (es) |
RU (1) | RU2020131402A (es) |
SG (1) | SG11202007117RA (es) |
TW (1) | TW202000650A (es) |
WO (1) | WO2019167981A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
WO2021149786A1 (en) | 2020-01-24 | 2021-07-29 | Japan Tobacco Inc. | Methods of treating cancer using dihydropyrimidin-2-one compounds |
WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4485107A (en) | 1982-11-01 | 1984-11-27 | Janssen Pharmaceutica N.V. | [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones |
CA2634152A1 (en) | 2005-12-22 | 2007-06-28 | Hydra Biosciences, Inc. | Trpa1 inhibitors for treating pain |
US20100010024A1 (en) | 2006-07-01 | 2010-01-14 | Bayer Healthcare Ag | Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension |
DE102006031314A1 (de) | 2006-07-01 | 2008-01-03 | Bayer Healthcare Aktiengesellschaft | Verwendung von 1,4-Diaryl-dihydropyrimidin-2-on-Derivaten zur Behandlung der pulmonalen arteriellen Hyptertonie |
WO2009150668A1 (en) | 2008-06-13 | 2009-12-17 | Delhi University | Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same |
WO2011115892A1 (en) * | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
MX2013012542A (es) | 2011-04-28 | 2013-11-20 | Japan Tobacco Inc | Compuestos de amida y aplicacion farmaceutica para el mismo. |
EP2682389A1 (en) | 2012-07-02 | 2014-01-08 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter |
JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
US10035790B2 (en) | 2012-10-19 | 2018-07-31 | Exelixis, Inc. | RORγ modulators |
WO2014065413A1 (ja) | 2012-10-26 | 2014-05-01 | 日本たばこ産業株式会社 | トリアゾール・イソオキサゾール化合物およびその医薬用途 |
CN103113308B (zh) | 2013-01-25 | 2014-11-19 | 浙江大学 | 一种制备二氢嘧啶酮衍生物的方法 |
WO2015095795A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
BR112017012136A2 (pt) | 2014-12-12 | 2018-01-02 | Merck Patent Gmbh | Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr |
AU2015360270B9 (en) | 2014-12-12 | 2019-12-05 | Regenacy Pharmaceuticals, Llc | Piperidine derivatives as HDAC1/2 inhibitors |
AU2015362394C1 (en) * | 2014-12-12 | 2021-01-28 | Japan Tobacco Inc. | Dihydropyrimidine-2-one compounds and medicinal uses thereof |
TW201630881A (zh) | 2014-12-12 | 2016-09-01 | H 朗德貝克公司 | 用於生產艾達魯吡啶之方法 |
US11358967B2 (en) * | 2016-01-20 | 2022-06-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma |
-
2019
- 2019-02-27 PE PE2020001289A patent/PE20210550A1/es unknown
- 2019-02-27 WO PCT/JP2019/007433 patent/WO2019167981A1/ja unknown
- 2019-02-27 MX MX2020008982A patent/MX2020008982A/es unknown
- 2019-02-27 AU AU2019228915A patent/AU2019228915A1/en not_active Abandoned
- 2019-02-27 CN CN201980015795.4A patent/CN111741947B/zh active Active
- 2019-02-27 CA CA3087994A patent/CA3087994A1/en active Pending
- 2019-02-27 US US16/287,870 patent/US10899717B2/en active Active
- 2019-02-27 RU RU2020131402A patent/RU2020131402A/ru unknown
- 2019-02-27 SG SG11202007117RA patent/SG11202007117RA/en unknown
- 2019-02-27 BR BR112020016785-1A patent/BR112020016785A2/pt not_active Application Discontinuation
- 2019-02-27 EP EP19759983.0A patent/EP3760616A4/en active Pending
- 2019-02-27 AR ARP190100480A patent/AR114270A1/es unknown
- 2019-02-27 JP JP2019033421A patent/JP7282546B2/ja active Active
- 2019-02-27 KR KR1020207024430A patent/KR20200126973A/ko not_active Application Discontinuation
- 2019-02-27 TW TW108106799A patent/TW202000650A/zh unknown
-
2020
- 2020-07-27 IL IL276323A patent/IL276323A/en unknown
- 2020-08-25 CL CL2020002187A patent/CL2020002187A1/es unknown
- 2020-08-27 PH PH12020551341A patent/PH12020551341A1/en unknown
- 2020-09-24 CO CONC2020/0011860A patent/CO2020011860A2/es unknown
- 2020-12-18 US US17/127,935 patent/US20210363110A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3760616A4 (en) | 2021-11-03 |
BR112020016785A2 (pt) | 2021-02-09 |
MX2020008982A (es) | 2020-09-28 |
RU2020131402A (ru) | 2022-03-24 |
US20210363110A1 (en) | 2021-11-25 |
TW202000650A (zh) | 2020-01-01 |
CA3087994A1 (en) | 2019-09-06 |
US20190300488A1 (en) | 2019-10-03 |
IL276323A (en) | 2020-09-30 |
JP2019151623A (ja) | 2019-09-12 |
US10899717B2 (en) | 2021-01-26 |
WO2019167981A1 (ja) | 2019-09-06 |
CN111741947B (zh) | 2024-06-11 |
SG11202007117RA (en) | 2020-08-28 |
KR20200126973A (ko) | 2020-11-09 |
EP3760616A1 (en) | 2021-01-06 |
PH12020551341A1 (en) | 2021-06-21 |
CO2020011860A2 (es) | 2021-01-18 |
AU2019228915A1 (en) | 2020-07-02 |
JP7282546B2 (ja) | 2023-05-29 |
PE20210550A1 (es) | 2021-03-17 |
CN111741947A (zh) | 2020-10-02 |
CL2020002187A1 (es) | 2020-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123260T1 (el) | Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου | |
CO2020000145A2 (es) | Carboxamidas como moduladores de los canales de sodio | |
CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
CL2020003257A1 (es) | Compuestos antagonistas de pcsk9. | |
AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
ECSP20025899A (es) | Compuestos útiles para inhibir a cdk7 | |
UY38837A (es) | Proceso de elaboración de moduladores de cftr | |
CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
ECSP088296A (es) | Compuestos terapéuticos | |
EA202193015A1 (ru) | Ингибиторы cdk | |
AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
AR114270A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmacéutico | |
EA202191286A1 (ru) | Ингибитор 15-pgdh | |
EA202090368A1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
AR117920A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
EA202191051A1 (ru) | Ингибитор аврора-киназы a для применения для лечения нейробластомы | |
UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
CL2019001804A1 (es) | Activador de nrf2. | |
MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
CL2020002199A1 (es) | Compuesto de anillo de metillactama y uso farmacéutico del mismo. | |
EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека | |
PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
AR110770A1 (es) | Moduladores del canal de potasio |